← Back to Search

Continuous Glucose Monitor

Continuous Glucose Monitoring for Diabetes in Hemodialysis Patients (DEXCOM-HD Trial)

N/A
Waitlist Available
Led By Connie Rhee, MD, MSc
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 to 5 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a continuous glucose monitor (CGM) is accurate compared to standard blood sugar tests in people with diabetes who are on dialysis.

Who is the study for?
This trial is for adults over 18 who are on hemodialysis due to kidney issues and also have diabetes. They must be patients at the University of California Irvine Medical Center with an expected hospital stay of at least 48 hours and can give informed consent.
What is being tested?
The study tests how well the Dexcom G6 Continuous Glucose Monitor tracks blood sugar levels compared to standard fingerstick or venous blood glucose measurements in hemodialysis patients with diabetes.
What are the potential side effects?
While not explicitly stated, potential side effects may include skin irritation from the CGM device adhesive, discomfort during sensor insertion, and possible inaccuracies leading to mismanagement of glucose levels.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 to 5 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 to 5 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blood glucose measurement
Secondary study objectives
Hypoglycemia events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dexcom G6 Continuous Glucose MonitorExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexcom G6 Continuous Glucose Monitor
2021
N/A
~30

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor
560 Previous Clinical Trials
1,930,072 Total Patients Enrolled
DexCom, Inc.Industry Sponsor
144 Previous Clinical Trials
35,455 Total Patients Enrolled
Connie Rhee, MD, MScPrincipal InvestigatorFaculty

Media Library

Dexcom G6 Continuous Glucose Monitor (Continuous Glucose Monitor) Clinical Trial Eligibility Overview. Trial Name: NCT04217161 — N/A
Hemodialysis Research Study Groups: Dexcom G6 Continuous Glucose Monitor
Hemodialysis Clinical Trial 2023: Dexcom G6 Continuous Glucose Monitor Highlights & Side Effects. Trial Name: NCT04217161 — N/A
Dexcom G6 Continuous Glucose Monitor (Continuous Glucose Monitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04217161 — N/A
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top